U.S. Capital Markets Stock News

If you are wondering whether Apple Hospitality REIT is attractively priced or not, a good starting point is to look at how its current share price lines up with different measures of value. The stock recently closed at US$11.63, with a 1% gain over the last week, a 4.2% decline over the last month, a 3.6% decline year to date, and an 18.2% return over the last year. These figures give you mixed signals about both risk and opportunity. Recent news coverage has focused on Apple Hospitality...

Madrigal Pharmaceuticals overview Madrigal Pharmaceuticals (MDGL) has been drawing closer attention after recent trading, with the stock closing at US$511.89 and showing mixed return patterns over the past year and past 3 months. See our latest analysis for Madrigal Pharmaceuticals. The 18.27% 1 month share price return contrasts with a 13.80% share price decline year to date. The 1 year total shareholder return of 69.06% points to stronger longer term momentum. If you are weighing Madrigal...

This article is designed to help you assess whether Bloom Energy's share price still reflects good value, or whether the story has moved ahead of the underlying numbers. Bloom Energy closed at US$135.91, with modest moves of 0.3% over the past week and 0.5% over the past month. Year to date it has returned 37.7%, its 1-year and 3-year returns are both roughly 7x and 6x respectively, and the 5-year return is also very large. Recent headlines around Bloom Energy have focused on the company's...

Intraday rally and options activity put Targa Resources in focus Targa Resources (TRGP) is back on traders' radar after a strong intraday rally pushed the stock near its 52 week high, with options activity picking up as volatility and leverage increase. See our latest analysis for Targa Resources. That options fueled move sits on top of strong momentum, with a 90 day share price return of 43.79% and a 1 year total shareholder return of 59.98%. These figures point to rising optimism around...

In early April 2026, Redwire Corporation announced a contract to supply its Hammerhead spacecraft and avionics for the European Space Agency’s Quantum Key Distribution Satellite program and opened a new UK office to support Ministry of Defence programs with dedicated local engineering and lifecycle support teams. Together, these moves extend Redwire’s secure-space and defence footprint across Europe, deepening ties with ESA and the UK Ministry of Defence while broadening its role in...

In early April 2026, Fluor Corporation announced it had been selected by America First Refining to execute front-end engineering and design for a large new refinery in Brownsville, Texas, and separately entered a contract with X-energy to provide Front-End Loading Stage 2 services for an advanced nuclear project at Dow’s Seadrift site. These wins position Fluor at the center of both the first new U.S. refinery in more than 50 years and one of the earliest grid-scale advanced nuclear...

In recent days, several Wall Street firms, including KeyBanc and Truist Securities, have initiated or reaffirmed positive coverage on Permian Resources, emphasizing its execution since the 2022 Centennial-Colgate merger and its focus on oil and natural gas development in the Permian Basin. This wave of analyst attention highlights growing institutional interest in the company’s operational progress and acquisition-driven model, potentially influencing how investors view its long-term growth...

Why Lennar’s recent guidance and land deal are in focus Lennar (LEN) is under close watch after weaker than expected fiscal first quarter guidance, an earnings miss, and fresh questions around its 8.5% land banking arrangement with Millrose Properties pressured the shares. See our latest analysis for Lennar. Lennar’s weaker fiscal first quarter guidance, earnings miss, and land banking scrutiny have coincided with a 15.4% 1 month share price decline and a 15.4% 1 year total shareholder...

Over the last 7 days, the United States market has risen by 1.2%, contributing to a remarkable 33% increase over the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, growth stocks with high insider ownership often signal strong confidence from those closest to the company, making them worth considering for their potential alignment with current market trends.

The market has climbed 1.2% in the last 7 days and is up 33% over the last 12 months, with earnings forecast to grow by 16% annually. Investing in penny stocks can still open doors to growth opportunities, typically in smaller or newer companies that come backed by strong financial health. Let's explore several penny stocks that could pair balance sheet strength with long-term potential.

The United States market has shown impressive momentum, climbing 1.2% in the last week and rising 33% over the past year, with earnings projected to grow by 16% annually. In such a dynamic environment, identifying stocks that offer unique value propositions and growth potential can be key to uncovering hidden opportunities.

The United States market has experienced a 1.2% increase over the last week and a notable 33% rise over the past year, with earnings projected to grow by 16% annually. In this thriving environment, identifying strong dividend stocks can be crucial for investors seeking both income and potential growth, as they offer regular payouts while potentially benefiting from overall market gains.

Recent Performance Snapshot Medpace Holdings (MEDP) has attracted attention after recent share price moves, with the stock up about 2.5% over the past day, 5.9% over the past week, and 8.1% over the past month. See our latest analysis for Medpace Holdings. That short term 1 day share price return of 2.5% and 1 month share price return of 8.1% sit against a 90 day share price decline of 17.1% and a 1 year total shareholder return of 83.4%. This suggests momentum has picked up again after a...

In recent days, Pinnacle West Capital has gained attention as one of the best utility dividend payers, while also advancing Arizona nuclear license renewal efforts and preparing to report its first-quarter 2026 results in early May after already releasing those figures. This combination of dividend focus and nuclear expansion potential is drawing interest to a company whose underlying operations and financial condition are still viewed as relatively weak and risky. We’ll now examine how...

Analyst coverage sparks fresh look at Dutch Bros Telsey’s new coverage of Dutch Bros (BROS), with a positive view on its loyalty program, comparable sales, and planned store expansion, has put the fast growing drive through coffee chain back on many investors’ radar. See our latest analysis for Dutch Bros. At a share price of US$53.03, Dutch Bros has recently seen a 7 day share price return of 4.68% and a 30 day share price return of 3.35%. Its 90 day share price return of 16.11% and 1 year...

Linde (LIN) is back in focus after William O'Neil initiated coverage, highlighting its strong market position, a reported US$10b project backlog, and ties to areas like clean hydrogen and semiconductor manufacturing. See our latest analysis for Linde. The recent 13.92% 90-day share price return and 21.27% 1-year total shareholder return suggest momentum has been building, as investors respond to Linde’s new US facility plans and the announcement of first quarter 2026 results. If you are...

A recent flood-related washout near Coloma forced CSX to shut down its rail line between Chicago and Grand Rapids, halting both freight operations and Amtrak’s Pere Marquette passenger service while repairs to the undermined track bed proceed. This disruption highlights how extreme weather can quickly strain rail reliability and raise short-term costs for infrastructure owners like CSX, even on well-used corridors. We’ll now examine how this weather-driven line shutdown, and the repair...

Fermi (FRMI) is back in focus after securing up to US$156.25 million in committed financing through a new senior unsecured promissory note, alongside recent equipment loans and fresh clean air permit applications for large scale power projects. See our latest analysis for Fermi. Despite announcing large financing facilities and expanded clean air permit applications, Fermi’s recent share price return has been weak. The 30 day share price return is 38.33% and the year to date share price...

Herbalife recently issued Q1 and full-year 2026 net sales growth guidance, projecting reported net sales to increase between 3.0% and 7.0% year over year for Q1 and 1.0% to 6.0% for 2026, prompting analysts to reassess the company’s turnaround prospects. The shift in analyst fair value estimates to US$16.50 highlights how updated guidance and evolving views on Herbalife’s turnaround are reshaping expectations for its business performance. We’ll now examine how Herbalife’s newly issued 2026...

Garmin’s Natural Cycles integration: what it could mean for the stock Garmin (GRMN) is drawing fresh attention after announcing a product integration with Natural Cycles, the FDA cleared birth control and fertility app, on select smartwatch models across multiple major markets. This partnership brings overnight skin temperature tracking from compatible Garmin devices directly into the Natural Cycles app, expanding Garmin’s women’s health capabilities and potentially strengthening the appeal...

AXIS Capital Holdings stock context AXIS Capital Holdings (AXS) has drawn investor attention after a period of mixed share performance, with the stock showing a 1 day decline of 0.38% and a past month decline of 1.90%. Over the past 3 months, AXIS Capital Holdings has recorded a 2.09% decline, while the 1 year total return stands at 16.11%, set against a market value of about US$7.5b. See our latest analysis for AXIS Capital Holdings. AXIS Capital Holdings’ recent 1 day and 3 month share...

In recent weeks, Agilent Technologies secured FDA approval for an expanded PD-L1 IHC 22C3 pharmDx cancer companion diagnostic indication and introduced the BioTek Cytation 9 cell imaging multimode reader, while the U.S. Supreme Court let stand rulings invalidating two of its CRISPR-related patents. This combination of a broader clinical diagnostic role alongside a new high-content lab instrument launch, set against a legal setback in gene-editing IP, reshapes how investors may view Agilent’s...

Assessing Deckers Outdoor after a mixed share price run Deckers Outdoor (DECK) has had a mixed share price run lately, with a 1 day decline, a modest gain over the past week, and negative returns over the month and past 3 months, prompting a closer look at fundamentals. See our latest analysis for Deckers Outdoor. At a share price of $100.26, Deckers Outdoor has seen recent share price pressure, with a 30 day share price return of 3.83% and a year to date share price return of 6.11%. Longer...

BioCryst Pharmaceuticals (BCRX) is in focus after appointing Sandeep M. Menon as Chief Research and Development Officer, a leadership change that directly ties to its rare disease pipeline and longer term R&D priorities. See our latest analysis for BioCryst Pharmaceuticals. At a share price of $9.59, BioCryst has seen a 30 day share price return of 13.09% and year to date share price return of 27.87%, while the 1 year total shareholder return of 48.22% points to building momentum around...